Stenocare AS's Total Assets for the quarter that ended in Mar. 2026 was €1.59 Mil.
During the past 12 months, Stenocare AS's average Total Assets Growth Rate was 230.90% per year.
During the past 3 years, the average Total Assets Growth Rate was -30.40% per year.
During the past 5 years, the average Total Assets Growth Rate was -17.10% per year.
During the past 8 years, Stenocare AS's highest 3-Year average Total Assets Growth Rate was 108.30%. The lowest was -30.40%. And the median was -1.50%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Stenocare AS's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Stenocare AS Total Assets Related Terms
Stenocare AS Total Assets Historical Data
* Premium members only.
The historical data trend for Stenocare AS's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Stenocare AS's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stenocare AS (FRA:S7C) has a Total Assets of €1.59 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Stenocare AS and its competitors.
Is Stenocare AS's Total Assets too high?
Stenocare AS's current Total Assets is €1.59 Mil. Overall, Stenocare AS has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Stenocare AS's Total Assets compare to ZTS and UTHR?
Stenocare AS's Total Assets of €1.59 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Stenocare AS and its competitors. Stenocare AS's current Total Assets is €1.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stenocare AS stock overvalued right now?
Based on GuruFocus' analysis, Stenocare AS (FRA:S7C) is currently considered Possible Value Trap. The stock's GF Value™ is €0.29, compared to a current price of €0.13 — trading 56.9% below its estimated fair value. The current Total Assets is €1.59 Mil. Stenocare AS's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Stenocare AS (FRA:S7C), the current Total Assets is €1.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stenocare AS (FRA:S7C) Overvalued in 2026?
Based on GuruFocus' analysis, Stenocare AS stock appears to be undervalued.
The current stock price of €0.13 is trading 56.9% below its estimated GF Value™ of €0.29.
GuruFocus considers Stenocare AS to be Possible Value Trap.
Key valuation signals for FRA:S7C:
Total Assets: €1.59 Mil
GF Value™: €0.29 vs. price of €0.13 (56.9% below fair value)
No single metric tells the full story. See the FRA:S7C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
34GF Score
Get the complete analysis for FRA:S7C
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S7C has been successfully added to your 
